

## PERFORMANCE IN INITIATING CLINICAL RESEARCH (Q1, 2017/18)

Research Ethics Committee Reference Number	Name of Trial	Date Site Selected	Date of First Patient Recruited	Benchmark Met?	Reason for not meeting benchmark
13/LO/1401	Focal RECurrent Assessment and Salvage Treatment	23/01/2017	26/04/2017	No	Delays in contract negotiation.
15/LO/1554	Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects	24/02/2017		No	Sponsor delays in providing IMP.
15/YH/0434	Dose Optimization Study of Idelalisib in Follicular Lymphoma and Small Lymphocytic Lymphoma.	25/01/2017		No	Rare disease; two potential patients screened but were not eligible.
16/EE/0133	Safety and proof of principle study of ATX-GD-59 in male and female subjects with Graves? disease not currently treated with anti-thyroid therapy: An Open label study, with an upward titration over five dose levels administered by Intradermal injection	22/03/2017	24/04/2017	Yes	Study met 70-day benchmark
16/LO/1452	Do statins increase sensitivity to glucagon?	25/01/2017	07/04/2017	No	Delays in providing IMP to site due to Sponsor changing IMP manufacturer; substantial amendment needed.
16/SC/0630	Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease	02/02/2017		No	Sponsor delays - set-up of system access for staff.
16/SC/0631	A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease GS-US-419-3896	03/02/2017		No	Extension study; no patients completed the feeder study within 70 days in order to be rolled into the extension.
16/YH/0004	A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Bruton's Tyrosine Kinase (BTK) Inhibitor	10/03/2017		No	Rare disease. Also one of the two IMPs for the study has only become available in the EU sites at the beginning of July 2017 (sponsor unaware of this).
17/HRA/0916	On-demand computerised decision making and syringe labelling in paediatric emergency prescribing: a workload and feasibility assessment.	01/03/2017	10/05/2017	Yes	Study met 70-day benchmark
10/H0803/121	Genetic Linkage Evaluation in Inherited Cardiac Conditions	18/01/2017	16/02/2017	Yes	Study met 70-day benchmark
12/NW/0361	A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANADII)	13/03/2017	29/03/2017	Yes	Study met 70-day benchmark
13/SC/0638	Human papillomavirus infection: a randomised controlled trial of Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac Trial)	12/10/2016	29/11/2016	Yes	Study met 70-day benchmark
15/LO/1044	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA1 trial)	07/11/2016	24/11/2016	Yes	Study met 70-day benchmark
15/LO/1553	ASSESSMENT OF MIDODRINE IN THE PREVENTION OF VASOVAGAL SYNCOPE: The Prevention of Syncope Trial IV (POST 4)	26/01/2017	06/03/2017	Yes	Study met 70-day benchmark
15/NE/0389	Phase 1 study to assess Single Doses of ABY-035 in Healthy Subjects and Psoriasis Patients	23/01/2017	25/04/2017	No	Delays negotiating contract between site and Sponsor.

15/NW/0385	A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 following Ascending Single and Multiple Oral Doses in Healthy Subjects and Multiple Oral Doses in Subjects with Rheumatoid Arthritis (RA) Also Treated with Methotrexate (MTX), the Effect of Food on the PK of MBS2320 in Healthy Subjects, the Relative Bioavailability in Healthy Subjects of Encapsulated Micronized MBS2320 versus MBS2320 in Suspension, and the PK Interaction of MBS2320 and MTX in Subjects with RA.	19/09/2016	03/11/2016	Yes	Study met 70-day benchmark
15/SC/0306	A phase 3,Randomized,Double-Blind,Placebo-Controlled Study of Ramacirumab plus Doxetacel vs Placebo plus Doxetacel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed or After Platinum-Based Therapy	09/09/2016	10/10/2016	Yes	Study met 70-day benchmark
16/EE/0009	A Phase 3,Randomized,Controlled, Multi-Center,Open-Label,Study To Compare Tivozanib Hydrochloride To Sorafenib In Subjects With Refractory Advanced Renal Cell Carcinoma	08/11/2016	16/12/2016	Yes	Study met 70-day benchmark
16/LO/0586	An Open Label Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients with Relapsing Remitting Multiple Sclerosis who have had a Suboptimal Response to an Adequate Course of Disease- Modifying Treatment	19/10/2016	16/11/2016	Yes	Study met 70-day benchmark
16/LO/0796	Prospective, non-randomized, safety and efficacy study of a new occluder design for minimally invasive closure of the left atrial appendage in patients with atrial fibrillation	04/07/2016	18/07/2016	Yes	Study met 70-day benchmark
16/LO/1169	Determining the effects of gut content on satiety	03/03/2017	09/03/2017	Yes	Study met 70-day benchmark
16/LO/1205	Feasibility and Acceptability of a Psychoeducational Booklet to Support Women who have been Prescribed Tamoxifen	21/10/2016	23/11/2016	Yes	Study met 70-day benchmark
16/LO/1250	A double blind, randomized, controlled study to assess the efficacy of continuous transversus abdominis plane (TAP) blocks for analgesia and enhanced recovery following major gynaecological surgery.	14/09/2016	25/10/2016	Yes	Study met 70-day benchmark
16/LO/1270	Increasing home practice during a novel mindfulness and acceptance based intervention for long-term conditions.	12/08/2016	29/08/2016	Yes	Study met 70-day benchmark
16/LO/1494	A Phase III, Randomised, Multicentre, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects	17/02/2017	20/03/2017	Yes	Study met 70-day benchmark
16/LO/1984	A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK- 3682 + MK-8408 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection	26/01/2017	20/02/2017	Yes	Study met 70-day benchmark
16/LO/2021	Effect of increased colonic propionate on weight loss during a hypo-caloric diet	13/02/2017	21/02/2017	Yes	Study met 70-day benchmark
16/NW/0169	An open-label, randomised, phase 2 study comparing S 95005 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated metastatic colorectal cancer who are non-eligible for intensive therapy	31/08/2016	31/10/2016	Yes	Study met 70-day benchmark
16/NW/0379	Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestininb or Placebo plus Gemcitabine and Cisplatin as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer	03/02/2017	26/02/2017	Yes	Study met 70-day benchmark
16/NW/0895	Feasibility study of a physical activity intervention in breast cancer survivors	12/01/2017	02/03/2017	Yes	Study met 70-day benchmark
16/SC/0441	A Phase 1, First-in-Humans, randomized, double-blind (within dose level),placebo-controlled trial to evaluate the safety and immunogenicity of two intranasal doses of SynGEM?, an intranasal Respiratory Syncytial Virus (RSV) subunit candidate vaccine based on the F glycoprotein linked to an immunostimulatory Bacterium-like-Particle (BLP) carrier administered 28 days apart in adult healthy volunteers	30/09/2016	21/10/2016	Yes	Study met 70-day benchmark
16/WA/0215	A Pilot Study to Evaluate Using Point of Care Thrombelastograph (TEG) Analysis in Major Trauma Patients within the Emergency Department	14/09/2016	22/09/2016	Yes	Study met 70-day benchmark

16/WM/0271	Prospective, Single-Arm, Multi-Centre Study to Evaluate the Contour Neurovascular System?	05/10/2016	02/12/2016	Yes	Study met 70-day benchmark
16/WM/0276	Safety of Nasal Influenza Immunisation in Children with asthma ? The SNIFFLE 4 study	19/09/2016	03/10/2016	Yes	Study met 70-day benchmark
16/YH/0022	A phase I, multicenter, open-label, single-sequence drugdrug interaction study to assess the effect of INC280 on the pharmacokinetics of midazolam and caffeine in patients with cMET-dysregulated advanced solid tumors	15/08/2016	17/10/2016	Yes	Study met 70-day benchmark
16/LO/0952	An open-label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for people with recently acquired hepatitis C virus infection with or without HIV co-infection.	05/08/2016	04/01/2017	No	Model CTA heavily modified by Sponsor; delays with contract negotiation.
16/LO/1318	Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance	08/11/2016	13/03/2017	No	Sponsor contract did not initially include key clauses in draft agreement, covering samples to be collected from patients.
14/SC/1416	A phase III multi-centre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the management of children with encephalitis	04/10/2016	13/02/2017	No	Very restrictive entry criteria and this is a rare disease cohort.
15/EM/0401	TRANSFORM-UK: A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension	16/11/2016	03/02/2017	No	Rare disease study.
15/WA/0395	A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)	19/07/2016		No	Rare disease study. 3 patients screened but all failed to date. Sponsor submitted an amendment to MHRA which delayed site set-up. Site delay in obtaining ARSAC.
16/EE/0386	A Multicentre, Randomised, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer	26/09/2016		No	Rare disease study. Sponsor informed site at SIV that recruitment halted across all UK sites in order to submit an amendment.
16/EE/0927	A Phase II, Multicenter, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis	04/11/2016		No	Rare disease study, patients screened but none eligible for the study.
16/EM/0032	A three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wt, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease	25/08/2016	16/01/2017	No	Study team actively recruiting; several potential patients identified but have failed screening.
16/EM/0376	The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods	20/10/2016		No	Sponsor submitted a protocol amendment which delayed site confirmation.
16/LO/0512	Intraocular pressure and tolerability Study of Preserved Bimatoprost 0.1% (BIMMD) or Tafluprost Unit Dose Preservative Free 15microgram/ml (TUDPF) (Safutan), in patients with Ocular hypertension or glaucoma suitable for prostaglandin therapy: A Randomized, single masked, 3 month cross-over, Investigator led, European multicentre Trial, II (SPORT II)	22/08/2016	09/01/2017	No	Difficult for patients; unwilling to consent.
16/LO/1891	A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepatitis (AH)	15/11/2016		No	Study opened over the summer months when cases of ARDs are less frequent; recruitment has been challenging nationally.
16/SS/0115	MK-8931-019: Long Term Safety and Efficacy Trial of MK-8931	23/08/2016	07/11/2016	No	Extension study - no patients completed feeder study within 70 days in order to be rolled into the extension.
16/WS/0005	A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHN'S DISEASE	16/01/2017		No	Very stringent inclusion criteria made it extremely challenging to find eligible patients. Site recruiting on time to meet target.

15/EE/0317	Does early targeted trunk training improve mobility outcome at 6 months for patients who are unable to sit unsupported at admission? A mixed method feasibility study	07/12/2016		No	Delays in internal reviews.
16/LO/1040	The effect of L-phenylalanine on appetite	31/08/2016		No	Staff absences (maternity leave).
16/LO/1263	Development of patient-specific tools to determine the need for adjunctive ablation following PVI for persistent AF using detailed characterisation of the substrate and the mode of recurrence	17/11/2016	15/03/2017	No	Required study team member not in the UK immediately after site was confirmed.
16/YH/0083	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma.	21/07/2016		No	Site pharmacy had drug administration issue in relation to the blinded/unblinded study drug.
17/LO/0052	Evaluation of Uterine Patency following Sonography-guided Transcervical Ablation of Fibroids	18/01/2017	03/04/2017	No	Sponsor delayed contract signature and SIV. Also staff availability issues.
14/LO/2182	A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patients with Unresectable Hepatocellular Carcinoma	02/08/2016	25/01/2017	No	Late protocol amendment which necessitated revision of costs / contract. Patients now consented and being screened.
14/SC/1072	In House' Preimplantation Oxygenated Hypothermic Machine Perfusion Reconditioning after Cold Storage versus Cold Storage alone in ECD Kidneys from Brain Dead Donors	07/10/2016	26/01/2017	No	Sponsor delays with contract. Then very challenging to identify suitable patients.
15/LO/1071	Primary Radiotherapy And DIEP flAp reconstruction	17/08/2016	08/02/2017	No	Sponsor delays (contract).
16/LO/0560	Can patient video testimonials augment the standard consent process? A Randomised Control Trial	29/11/2016		No	Technical issues with Sponsor's website which displays the video required for the intervention. Study team unable to recruit as consent occurs on the same day as the intervention.
16/LO/0886	A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke	29/09/2016	15/12/2016	No	Delay in activating site and supplying equipment needed for recruitment.
16/LO/1854	A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are at Risk of HIV-1 Infection	14/12/2016	21/03/2017	No	Sponsor delayed site activation; then closed site without activating.
16/SC/0617	A Randomised Pilot Multiple Centre Trial of Conservative versus Liberal Oxygenation Targets in Critically Ill Children	12/11/2016	09/03/2017	No	Sponsor delays with contract and providing randomisation tool. Randomisation tool unavailable and site not able to start recruiting until 06/03/2017.
16/SW/0232	A multi-centre, double-blind, randomised, controlled clinical trial of Rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis	31/10/2016	12/01/2017	No	Sponsor delay - postponed start of recruitment to January 2017 (site confirmed in November 2016). Site waiting for study drug to be delivered.
14/LO/1206	Planning Treatment For Oesophago-Gastric Cancer: a Randomised Maintenance Therapy Trial	06/12/2016		No	Sponsor submitted late amendment; then Sponsor unavailable to perform site activation for 5 weeks after site confirmed.
15/LO/1595	Prevention of Respiratory Insufficiency after Surgical Management (PRISM) Trial: A pragmatic randomised controlled trial of continuous positive airway pressure (CPAP) to prevent respiratory complications and improve survival following major abdominal surgery	11/10/2016	25/01/2017	No	Delay in internal site reviews and approvals.
15/SC/0409	Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration	15/08/2016		No	Long contract/budget negotiations between Sponsor and site. Study was closed globally 1 month after recruitment had been opened.
16/EE/0357	Efficacy and safety of opicapone in clinical practice in Parkinson's Disease patients with wearing-off motor fluctuations	22/11/2016	17/05/2017	No	Long contract/budget negotiations between Sponsor and site.
16/LO/0443	A multicentre, open-label, multiple-dose study to evaluate the safety, tolerability and efficacy of UCB7665 in subjects with primary immune thrombocytopenia	15/11/2016		No	Due to wash out period of 3 months required by this trial, the first patient could not be recruited until April 2017.
16/LO/0542	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)	22/11/2016	22/02/2017	No	9 patients screened but none eligible to be recruited.

16/LO/1350	OPTIC - Optical Polyp Testing for In vivo Classification	29/11/2016	07/03/2017	No	Challenging timing for study team as end of year made access to specific clinical equipment difficult. Also restrictions on patient access to the specific endoscopy required by study. Staff unavailability.
16/LO/1584	Spectroscopy for blood perfusion monitoring	10/01/2017		No	Strict recruitment criteria has made recruitment very challenging. PI is looking at ways of amending the recruitment strategy.
16/LO/1700	A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis	13/01/2017	08/02/2017	Yes	Study met 70-day benchmark.
16/NE/0142	A Randomized, Open-label, Multicenter, Phase 3 study to evaluate the efficacy and safety of Avelumab (MSB0010718C) in combination with and/or following chemotherapy in patients with previously untreated epithelial ovarian cancer?	01/11/2016	24/01/2017	No	Delays in internal reviews and approvals.
16/NE/0279	Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)	29/09/2016		No	Delays in internal reviews and approvals. Rare disease study.
16/SC/0277	Point of Care Testing for Sepsis in ICU Patients: A Diagnostic Accuracy Study	04/10/2016	17/05/2017	No	Sponsor delay in sending study supplies to site and training site staff.
16/SC/0390	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing forms of multiple sclerosis	10/01/2017		No	Strict eligibility criteria made identifying patients extremely challenging.
16/SC/0422	A PHASE 2A STUDY OF TRC105 (WITH OPTION TO ADD STANDARD DOSE BEVACIZUMAB) IN PATIENTS WITH REFRACTORY GESTATIONAL TROPHOBLASTIC NEOPLASIA (GTN)	14/12/2016		No	GCP course refresher required. Also rare disease study.
17/LO/0173	Clinical application and evaluation of advanced diagnostic tools in women with suspected endometrial cancer.	01/02/2017	13/06/2017	No	Delay with HRA.
17/LO/0047	Enhanced Personalised and Integrated Care for Infection Management at the Point of Care - EPIC IMPOC	23/03/2017	08/05/2017	Yes	
16/NI/0221	Modulation of a gene cluster in patients with epilepsy	23/03/2017		No	Limited number of patient population eligible for the study.
16/LO/1258	Randomised Clinical Trial of Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease	20/01/2017		No	Sponsor delayed SIV / "green light" (pharmacy IMP info).
16/SC/0601	A long term extension study to evaluate the safety of Filgotinib in Subjects with Ulcerative Colitis	04/04/2017		No	Extension study which is not due to start recruitment until patients complete the feeder study. Sponsor wanted to complete set-up early and informed sites 70 day benchmark not expected to be met.
17/EM/0116	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose Wearing-Off?	01/06/2017		Within 70 Days	70 day benchmark not yet due.
16/WM/0006	WHIST - Wound Healing In Surgery for Trauma. A Randomised Controlled Trial of standard wound management versus negative pressure wound therapy in the treatment of adult patients having surgical incisions for major trauma to the lower limb	18/01/2017	15/06/2017	No	Delays in contract negotiations.
16/LO/1812	Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF)	07/02/2017		No	Heavily modified model agreement requested by Sponsor, which prolonged review and negotiation.
17/LO/0444	A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-ActingAntiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection	08/06/2017	15/06/2017	Yes	Study met 70 day benchmark.
17/LO/0401	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies.	23/03/2017	06/06/2017	No	Delays in contract negotiations.
16/LO/1514	A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma	21/10/2016		No	Delays in contract negotiations.
16/EE/0190	Supportive Exercise Programmes for Accelerating Recovery after major Abdominal Cancer surgery	26/07/2016		No	Delays in contract negotiations.

17/LO/0037	A novel robotic system for trans-anal surgery	30/03/2017		No	Delay with HRA.
16/LO/0581	Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PK Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in women With Advanced, Recurrent, or Persistent Endometrial Cancer.	16/08/2016	12/01/2017	No	Delays in contract negotiations. Also delay with site pharmacy.
16/SC/0653	A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	11/04/2017		No	Sponsor delayed contract negotiations; lack of communication.
16/LO/2148	A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Significant, Localised, Low- to Intermediate-Risk Prostate Cancer that is Associated with an MRI Lesion	10/02/2017	21/06/2017	No	Sponsor delay in supplying IMP and pharmacy file to site.
17/LO/0524	Catheter Ablation of Low Voltage regions in the treatment of persistent Atrial Fibrillation (ABLOVO-AF study)	18/05/2017		Within 70 Days	Sponsor submitting amendment after initial document pack was received; recruitment on hold until amendment has been processed.
17/EM/0005	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction	24/02/2017		No	Delays with costing negotiations.
17/LO/0465	ADJUNCTIVE GP ABLATION IN REDO-PVI STUDY (ADD-GP): PAROXYSMAL ATRIAL ARRHYTHMIAS AFTER PULMONARY VEIN ISOLATION ARE DRIVEN BY ECTOPY-TRIGGERING LEFT ATRIAL GANGLIONATED PLEXI	21/04/2017	19/06/2017	Yes	
16/EM/0181	Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms	27/07/2016		No	Delays in contract negotiations. Rare disease cohort.